Abstract
44
Breast cancer is a leading cause of death in women mainly due to the propensity of breast tumors to metastasize to 45 regional and distant sites, such as the lymph node, lung, liver, bone and brain [1] . The incidence of brain metastases 46 is increasing due to the introduction of more sensitive diagnostic methods and improved systemic therapies leading 47 to improvements in extra-cranial control and survival [2] [3] [4] . Breast cancer is a disease with a number of subtypes and 48 patients with metastatic 'triple-negative' breast cancer tend to develop brain metastasis at a high rate [5, 6] . For the 49 HER2 amplified subtype, the frequency of brain metastasis has been reported to be as high as 50% [7] .
51
Once a metastatic cancer cell arrives in the brain one of three things can happen: (1) it may die, (2) it may proliferate 52 to form micrometastases, or (3) it may remain viable but dormant ('non-proliferative') [8, 9] If the solitary cells 53 proliferate to form micrometastases, they may again experience one of three fates: (1) they may die, (2) they may 54 continue to proliferate and form macrometastases, or (3) they may persist as "dormant" micrometastases, where 55 dormancy is defined as a balance between proliferation and apoptosis within the cell population such that there is no 56 net growth [9, 10] . The factors that tip the balance between dormancy and proliferation are poorly understood. Both 57 dormant single cells and dormant micrometastases are believed to be sources of cells that contribute to tumor 58 recurrence [11] . Dormant cancer cells also present a substantial therapeutic problem; since they are quiescent, they 59 are non-responsive to current therapies which target proliferating cells [8] .
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Currently, only a handful of models specific to breast cancer brain metastasis have been described and even fewer 62 allow for in vivo investigation of cancer cell dormancy. Both murine and human cancer cell lines have been 63 developed to mimic as many steps in the metastatic cascade as possible. A well characterized murine breast cancer 64 cell line is the 4T1-BR5 cell line, a highly tumorigenic and invasive cell line that has undergone multiple rounds of 65 selection to preferentially grow in the mouse brain [12] . There are several advantages to using a murine breast 66 cancer cell line to study brain metastasis, as growth and maintenance is easy and relatively inexpensive, and it can 67 be grown in immune-competent mice, which is of particular interest for studying this disease in a way that 68 recapitulates the tumor microenvironment [13] . 71   commonly used MDA-MB-231BR (231BR), MDA-MB-231BR-HER2, MA11, JIMT1-BR3, SUM190-BR3 cell   72 lines. The MDA-MB-231BR cell line has been particularly well characterized for studying the progression of brain 73 metastases in nude mice. Nude mice are the most commonly used immune-deficient strain for models which use 74 human cell lines. They have a genetic mutation that causes a deteriorated or absent thymus, resulting in a lack of T 75 cells [14] . The 231BR cell line grows selectively in the brain of nude mice, without metastatic growth seen in other 76 distant organs [15] . Human breast cancer cell lines are one of the most widely used models to study the metastatic 77 growth of cancer in vitro and in vivo, as they have been used to provide extensive insight into the characteristics of 78 human cells and can be used for high throughput screening of various drugs [16] . There are, however, significant 79 limitations to using human and murine breast cancer cell lines, as the quick progression in vivo can limit 80 opportunities for adequate therapeutic testing, and the growth of these cells in vitro prior to establishment in a mouse 81 can cause changes in the genetic composition due to clonal selection [17] . Many groups have shown that these 82 genetic changes result in these models failing to maintain tumor heterogeneity, which is now recognized as a critical 83 element for developing personalized treatments [18] [19] [20] . Studying breast cancer with immunocompetent mice also 84 has limitations, as tumor latency and growth can be variable and slow [21] . There is also increased difficulty in 85 establishing human tumors successfully in these mice. Immune-compromised mice lack a comparable tumor 86 microenvironment to clinical tumors and fail to provide a realistic result of interactions with the natural immune 87 response, particularly in the case of studying anticancer therapeutics [22] .
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In more recent years, researchers have moved towards studying breast cancer and its subtypes with patient-derived 90 xenografts (PDX), which allow for the growth of human primary breast cancer tissue that has been recently resected 91 from consenting patients into immune-compromised rodents [23] 
299
The 231BR cell line was developed by Yoneda et al [15] . and is a brain-colonizing subline of the metastatic triple-300 negative MDA-MB-231 human breast cancer cell line, which was isolated by six repeated cycles of intra-cardiac 301 injection and harvesting from brain metastases grown in nude mice. In our lab, the intra-cardiac injections are nanoparticle, which causes a local magnetic field inhomogeneity [34] . We have previously shown that we can detect 317 single iron-labeled cells arrested in the mouse brain using cellular MRI [35, 39, 40] . Our image showed that the 318 number of signal voids in the brain was similar for nude and NSG mice on day 0 and at endpoint. While we 319 acknowledge that there is potential for immune cell uptake of the iron oxide nanoparticles that may be released by 
